Ipsen Past Earnings Performance

Past criteria checks 3/6

Ipsen has been growing earnings at an average annual rate of 22%, while the Pharmaceuticals industry saw earnings growing at 0.5% annually. Revenues have been growing at an average rate of 6.1% per year. Ipsen's return on equity is 16.2%, and it has net margins of 18.7%.

Key information

22.0%

Earnings growth rate

22.2%

EPS growth rate

Pharmaceuticals Industry Growth	6.0%
Revenue growth rate	6.1%
Return on equity	16.2%
Net Margin	18.7%
Next Earnings Update	25 Jul 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown
Beta

How Ipsen makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OTCPK:IPSE.F Revenue, expenses and earnings (EUR Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Dec 23	3,306	617	1,135	619
30 Jun 23	3,282	406	1,105	528
31 Mar 23	3,219	500	1,072	487
31 Dec 22	3,156	593	1,039	445
30 Sep 22	3,053	656	1,007	436
30 Jun 22	2,950	719	975	427
31 Mar 22	2,849	675	946	425
31 Dec 21	2,749	631	916	424
30 Sep 21	2,712	626	923	422
30 Jun 21	2,676	622	931	420
31 Mar 21	2,681	585	951	413
31 Dec 20	2,686	548	972	406
30 Sep 20	2,697	249	986	404
30 Jun 20	2,707	-50	1,000	403
31 Mar 20	2,700	-53	1,010	396
31 Dec 19	2,693	-55	1,021	389
30 Sep 19	2,605	176	1,003	363
30 Jun 19	2,516	406	986	337
31 Mar 19	2,432	397	970	319
31 Dec 18	2,348	388	954	302
30 Sep 18	2,258	365	931	292
30 Jun 18	2,167	343	909	281
31 Mar 18	2,090	307	883	274
31 Dec 17	2,012	270	858	266
30 Sep 17	1,923	243	821	264
30 Jun 17	1,834	217	785	262
31 Mar 17	1,753	221	752	247
31 Dec 16	1,671	226	719	231
30 Sep 16	1,623	229	703	214
30 Jun 16	1,575	233	687	196
31 Mar 16	1,548	211	676	194
31 Dec 15	1,520	189	666	193
30 Sep 15	1,468	165	651	192
30 Jun 15	1,416	140	636	191
31 Mar 15	1,374	147	606	189
31 Dec 14	1,332	154	577	187
30 Sep 14	1,310	155	557	190
30 Jun 14	1,287	156	537	193
31 Mar 14	1,284	149	543	194
31 Dec 13	1,282	142	549	196
30 Jun 13	1,283	87	571	220

Quality Earnings: IPSE.F has high quality earnings.

Growing Profit Margin: IPSE.F's current net profit margins (18.7%) are lower than last year (18.8%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: IPSE.F's earnings have grown significantly by 22% per year over the past 5 years.

Accelerating Growth: IPSE.F's earnings growth over the past year (4%) is below its 5-year average (22% per year).

Earnings vs Industry: IPSE.F earnings growth over the past year (4%) exceeded the Pharmaceuticals industry -0.5%.

Ipsen Past Earnings Performance

Past criteria checks 3/6

Key information

Recent past performance updates

Ipsen S.A. to Report Q4, 2023 Results on Feb 08, 2024

Ipsen S.A. to Report First Half, 2024 Results on Jul 24, 2024

Ipsen S.A. to Report Fiscal Year 2022 Results on Feb 09, 2023

Ipsen S.A. to Report Q2, 2023 Results on Jul 27, 2023

Ipsen S.A. to Report Q3, 2022 Results on Oct 26, 2022

Recent updates

Ipsen Announces Executive Changes

Ipsen’s Onivyde Regimen, Potential New Standard-Of-Care First-Line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA

Ipsen Announces Latest Phase III Trial Data Investigating Cabometyx®? in Combination with Immunotherapy to Be Present at ASCO Gu 2024

Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare, Cholestatic Liver Disease, PBC

Ipsen and GENFIT Announces Full Results from the Pivotal Phase III ELATIVE Trial

Ipsen S.A. to Report Q4, 2023 Results on Feb 08, 2024

Ipsen S.A. to Report First Half, 2024 Results on Jul 24, 2024

IRLAB Therapeutics AB Announces Further Information on Results from Mesdopetam’s Clinical Phase IIb Study in Parkinson’s Disease Levodopa-Induced Dyskinesias and Phase III Preparatory Phase I Studies Performed by Ipsen

Ipsen Provides Update on E.U. Marketing Authorization Application for Bylvay for Cholestatic Pruritus in Patients with Alagille Syndrome

Ipsen Announces European Commission Decision on Palovarotene for the Treatment of FOP

Ipsen and GENFIT Announces Positive Results from Phase III ELATIVE Trial of Elafibranor in Patients with Primary Biliary Cholangitis, A Rare Cholestatic Liver Disease

Ipsen Announces U.S. FDA Submission Acceptance of Its Supplemental New Drug Application for Onivyde Regimen in First-Line Metastatic Pancreatic Ductal Adenocarcinoma

Ipsen Announces U.S. FDA Approves Bylvay® for Patients Living with Cholestatic Pruritus Due to Alagille Syndrome

Ipsen to Present New Data

Ipsen S.A. Approves Dividend, Payable on 6 June 2023

Ipsen S.A. Proposes Final Dividend for the Financial Year 2022, Payable on June 6, 2023

Ipsen S.A. Provides Earnings Guidance for the Full Year 2023

Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U

Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde(R) Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma At Asco GI

Ipsen S.A. (ENXTPA:IPN) entered into a definitive merger agreement to acquire Albireo Pharma, Inc. (NasdaqCM:ALBO) for approximately $870 million.

Ipsen S.A. Provides Update on Phase III CONTACT-01 Trial Evaluating Cabozantinib

Ipsen Announces Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Ipsen S.A. Provides Earnings Guidance for the Financial Year 2023

Ipsen S.A. to Report Fiscal Year 2022 Results on Feb 09, 2023

Ipsen S.A. to Report Q2, 2023 Results on Jul 27, 2023

Ipsen S.A. to Report Q3, 2022 Results on Oct 26, 2022

Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde in Second-Line Monotherapy for Small Cell Lung Cancer

Ipsen S.A. Upgrades Earnings Guidance for the Full Year 2022

Ipsen Announces U.S. FDA Priority Review for Palovarotene New Drug Application in Patients with Fibrodysplasia Ossificans Progressiva Following Resubmission

Ipsen Announces at ASCO 2022 New Cabometyx Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types

Ipsen S.A. Approves Dividend, Payable on 2 June 2022

Ipsen S.A. Approves Dividend, Payable on 2 June 2022

Ipsen S.A. Proposes Dividend for the Financial Year 2021, payable on 2 June 2022

Exelixis, Inc. Partner Ipsen Receives European Commission Approval for Cabometyx® (Cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Ipsen S.A. Provides Sales Guidance for the Year 2022

Ipsen Appoints Catherine Abi-Habib as EVP Strategy, Transformation, and Digital

Ipsen S.A. Announces Two-Year Follow-Up Results from Analyses of the Phase III Checkmate -9ER Trial

Ipsen S.A. Proposes Dividend for the Year 2021

Ipsen Announces the Health Canada Approval of Sohonos as the First Treatment for Fibrodysplasia Ossificans Progressiva

Revenue & Expenses BreakdownBeta

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Revenue & Expenses Breakdown
Beta